Getting the Timing Right: Controlling BCL-2 Inhibition as an Antifibrotic Therapy
Progressive fibrosing interstitial lung diseases (PF-ILDs), such as idiopathic pulmonary fibrosis (IPF), have pathophysiologic overlap, including accumulation of apoptosis-resistant profibrotic fibroblasts and senescent epithelial cells. Early and repetitive injury to the epithelium is thought to contribute to the eventual development of fibrosis and progressive scarring, but the exact early mechanistic events that lead to progressive fibrosis are often unknown. Thus, there has been limited ability to